Announced Date: 2025-04-18 (April 18, 2025)
Asset Name: VBS-102
Licensor: VelaVigo Bio (China)
Licensee (Buyer): Ollin Biosciences (USA)
.
Asset Modality: BsAbs (Bispecific antibody)
Asset Target: IGF-1R/TSHR
Current Stage:
.
Scope of Authority:
VelaVigo has granted Ollin an exclusive license to develop, manufacture and commercialize VBS-102, a first-in-class bispecific antibody, globally (excluding Greater China).
VelaVigo will maintain rights for Greater China.
.
Payment Detail:
VelaVigo will receive:
Upfront fee and future development, regulatory, and commercial milestone payments in cash and equity, totaling up to approximately $440 million in the aggregate,
as well as tiered royalties on sales in Ollin’s territory.
.
Link:
VelaVigo Announces Second Out-Licensing Deal, of a First-in-Class Bi-specific Antibody, Further Validating Its Innovative Discovery Platform and Sustainable BD+VC Business Model
